Nektar Therapeutics
R Scott Greer (Director) reports NKTR insider transactions
About this filing
Nektar Therapeutics (NKTR) filed Form 4 (insider transaction) with the SEC on Sep 25, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- R Scott Greer · Director
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | A · grantFootnotes F1, F2, F3 | +2,000 | $0.00 | $0.00 | 22,239 | Direct |
| Sep 23, 2026 | A · grantStock OptionFootnotes F4 | +4,000 | $0.00 | $0.00 | 4,000 | Direct |
Footnotes
- F1 Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
- F2 This RSU award vests in full, one year following September 23, 2026.
- F3 On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
- F4 This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.
More NKTR filings
- S-8
Filed Oct 19, 2026
- 8-K
Filed Oct 1, 2026
- SC 13G/A
Filed Sep 28, 2026
- 4
Filed Sep 25, 2026
- 4
Filed Sep 25, 2026
- 4
Filed Sep 25, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.